Renal function after liver transplantation: Real-world experience with basiliximab induction and delayed reduced-dose tacrolimus

Cederborg, Anna; Norén, Åsa; Barten, Thijs; Lindkvist, Björn; Bennet, William; Herlenius, Gustaf; Castedal, Maria; Marschall, Hanns‐Ulrich; Åberg, Fredrik

doi:10.1016/j.dld.2021.12.006

Cited by 2 publications

(1 citation statement)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Postoperatively, standing mycophenolate mofetil is started the evening of day zero and tacrolimus on day one or two depending on the patient’s baseline renal function. While these doses are relatively constant, another agent, basiliximab, is administered intraoperatively after methylprednisolone for patients with a creatinine clearance of < 60 mL/min to delay initiation of reduced-dose tacrolimus in an effort to reduce kidney injury [ 48 ]. The specific immunosuppressive agents and timing of administration will be recorded for each patient.…”

Section: Discussionmentioning

confidence: 99%

OXIDATIVE study: A pilot prospective observational cohort study protocol examining the influence of peri-reperfusion hyperoxemia and immune dysregulation on early allograft dysfunction after orthotopic liver transplantation

Wilson,

Woodbury,

Williams

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

Early allograft dysfunction (EAD) is a functional hepatic insufficiency within a week of orthotopic liver transplantation (OLT) and is associated with morbidity and mortality. The etiology of EAD is multifactorial and largely driven by ischemia reperfusion injury (IRI), a phenomenon characterized by oxygen scarcity followed by paradoxical oxidative stress and inflammation. With the expanded use of marginal allografts more susceptible to IRI, the incidence of EAD may be increasing. This necessitates an in-depth understanding of the innate molecular mechanisms underlying EAD and interventions to mitigate its impact. Our central hypothesis is peri-reperfusion hyperoxemia and immune dysregulation exacerbate IRI and increase the risk of EAD. We will perform a pilot prospective single-center observational cohort study of 40 patients. The aims are to determine (1) the association between peri-reperfusion hyperoxemia and EAD and (2) whether peri-reperfusion perturbed cytokine, protein, and hypoxia inducible factor-1 alpha (HIF-1α) levels correlate with EAD after OLT. Inclusion criteria include age ≥ 18 years, liver failure, and donation after brain or circulatory death. Exclusion criteria include living donor donation, repeat OLT within a week of transplantation, multiple organ transplantation, and pregnancy. Partial pressure of arterial oxygen (PaO2) as the study measure allows for the examination of oxygen exposure within the confines of existing variability in anesthesiologist-administered fraction of inspired oxygen (FiO2) and the inclusion of patients with intrapulmonary shunting. The Olthoff et al. definition of EAD is the primary outcome. Secondary outcomes include postoperative acute kidney injury, pulmonary and biliary complications, surgical wound dehiscence and infection, and mortality. The goal of this study protocol is to identify EAD contributors that could be targeted to attenuate its impact and improve OLT outcomes. If validated, peri-reperfusion hyperoxemia and immune perturbations could be targeted via FiO2 titration to a goal PaO2 and/or administration of an immunomodulatory agent by the anesthesiologist intraoperatively.

show abstract

Section: Discussionmentioning

confidence: 99%